A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05879926

Clinical trials study type

Oncology - Breast

Clinical trials trial status

Open to Accrual

IRB number

2151828

Principal investigator

Robert Donegan, MD

Clinical trials study number

NRG-BR009

Clinical trials title (full)

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25 (OFSET)